Medical/Pharmaceuticals
Immunocan Provides Update on Business Operations, Highlighting Launch of New Gene-edited Mice Generating Fully Human Heavy-chain-only Antibodies and Advances in Partner Pipeline
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Shanghai Immunocan Biotech Co., Ltd. ("Immunocan") announcesthe launch of its ImmuMab Heavy® mice. These gene-edited mice, developed by modifying the constant region genes of heavy chains in the ImmuMab® mouse, generate fully human heavy-chain-only antibodi...
2023-12-13 22:00
1936
Molecular Loop Biosciences Receives $1.8 Million to Expand Multi-pathogen Genomics Products for Respiratory Infections
WOBURN, Mass., Dec. 13, 2023 /PRNewswire/ -- Molecular Loop Biosciences, Inc., an innovator at the forefront of targeted sequencing technologies, is pleased to announce that it has received a$1.8 million grant from the Bill & Melinda Gates Foundation to further its groundbreaking work in the fiel...
2023-12-13 21:00
1650
Imagion Announces Positive Results from IBI10103 Phase I Study Demonstrating Safety and Clinical Feasibility of Molecular MRI with MagSense® HER2 Imaging Agent
MELBOURNE, Australia and SAN DIEGO, Dec. 13, 2023 /PRNewswire/ -- Imagion Biosystems Limited (ASX: IBX) recently announced positive results following completion of the IBI10103 phase I clinical trial evaluating the safety and clinical feasibility ofMagSense® HER2 Imaging Agent (MSH2IA) as an adju...
2023-12-13 19:00
1895
Transcenta Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging
PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces ...
2023-12-13 18:01
2240
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
ROCKVILLE, Md. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-13 12:56
3103
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage--
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
2023-12-13 07:42
1859
The NDA for New Indication of Henlius Anti-PD-1 mAb Serplulimab in Combination with Chemotherapy for the First-line Treatment of non-squamous NSCLC Accepted by the NMPA
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that the NDA for new indication of HANSIZHUANG, serplulimab, an innovative anti-PD-1 mAb independently developed by the company, in combination with chemotherapy as a first-line treatment for patients with...
2023-12-12 20:30
2206
Illumina partners with HaploX to build a domestically produced flagship benchtop sequencing system
SHENZHEN, China, Dec. 12, 2023 /PRNewswire/ -- On December 9, Illumina, a global leader in DNA sequencing and array-based technologies, and HaploX, aChina -based high-tech company specializing in oncology liquid biopsy and genetic big data, jointly announced the official launch of the first NextSe...
2023-12-12 17:31
2424
ICP DAS - BMP's Medical-Grade TPU Takes Center Stage at Top Global Medical & Plastic Exhibitions
HSINCHU, Dec. 12, 2023 /PRNewswire/ -- ICP DAS (3577-TW) New Business Unit, ICP DAS – BMP, actively ramps up medical-grade TPU (thermoplastic polyurethane) development and production as well as international marketing. The company's participation at COMPAMED and IPF Japan has been a resounding su...
2023-12-12 16:51
2467
Qilu Pharmaceutical Announces Results from Phase I Clinical Study for Its Novel Bispecific Antibody QLS31905 at ESMO Immuno-Oncology Congress
JINAN, China, Dec. 12, 2023 /PRNewswire/ -- During the ESMO Immuno-Oncology Congress 2023 held inGeneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster prese...
2023-12-12 11:04
1936
Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
* ELEVATE and ELECTRA studies were designed with the objective to overcome different treatment resistance mechanisms and enhance patient outcomes with oral-oral combination options. * A preliminary analysis of data in the phase 1b part of the ELEVATE trial demonstrates antitumor activity of t...
2023-12-12 00:42
2745
Inovalon Applauded by Frost & Sullivan for Improving Healthcare Delivery, Patient Outcomes, and Data Security with Its Inovalon ONE® Platform
Inovalon ONE® Platform seamlessly aggregates, standardizes, and analyzes diverse data to gain meaningful insights, support evidence-based decision-making, and offer data security and privacy. SAN ANTONIO, Dec. 11, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the healthcare analytics...
2023-12-11 22:00
1516
First Patient Dosed in U.S. Expanded Access Program for TLX250-CDx, Telix's Breakthrough Kidney Cancer Imaging Agent
MELBOURNE, Australia and INDIANAPOLIS, Dec. 11, 2023 /PRNewswire/ -- Telix
Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the
first patient has been dosed in aUnited States (U.S.) expanded access program
(EAP, ClinicalTrials.gov ID:NCT06090331
2023-12-11 19:40
1458
Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer
SAN FRANCISCO and SINGAPORE, Dec. 11, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Offi...
2023-12-11 18:00
1633
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will evaluate the safety and preliminary efficacy of ATG-031 in patients withadvanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). * ATG-031, discovered and developed in-house by Antengene, is t...
2023-12-11 08:30
1638
Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023
* This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations. * This analysis shows a clinically meaningful improvement in progression-free survivala...
2023-12-08 23:13
3671
Whole Exome Sequencing Advancements in Unraveling Rare Diseases in Japan
TOKYO, Dec. 8, 2023 /PRNewswire/ -- According to Estimation of the Number of
Patients With Mitochondrial Diseases: A Descriptive Study Using in a nationwide
database inJapan
2023-12-08 13:40
1881
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. * This marks the 13th NDA approval obtained by CSt...
2023-12-08 12:10
5537
CU Medicine study published in The Lancet Infectious Diseases concludes that a novel oral microencapsulated live bacteria consortia (SIM01) alleviates long COVID symptoms
HONG KONG, Dec. 8, 2023 /PRNewswire/ -- A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by TheChinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula (SIM01)...
2023-12-08 10:38
2250
Unlocking the Potential of Multi-Omics in Precision Medicine: A Conversation with Kazusa DNA Research Institute
CHIBA, Japan, Dec. 7, 2023 /PRNewswire/ -- The integration of multi-omics approaches offers a comprehensive panorama for advancing our comprehension of biology. It now plays a more important role in understanding the roots of diseases, and in expediting precision medicine and catalyzing advanceme...
2023-12-07 15:37
1882
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
